TrialJAMA oncology2018

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.

John Mascarenhas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.